Literature DB >> 17523583

Is recreational ecstasy (MDMA) use associated with higher levels of depressive symptoms?

Casey Guillot1.   

Abstract

Due to potential serotonergic deficits, 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) may cause long-term mood disruptions in recreational Ecstasy users. The purpose of this review is to evaluate the evidence for a relationship between recreational Ecstasy use and higher levels of depressive symptoms. Eleven out of 22 studies initially have reported significantly higher depression scores in Ecstasy users in comparison to control participants. However, only three studies ultimately have revealed significantly higher depression scores in comparison to cannabis or polydrug controls. Furthermore, most studies have suffered from methodological weaknesses, and the levels of depressive symptoms that have been found in Ecstasy users have not been shown to be much higher than those found in normative groups. The evidence for an association specifically between Ecstasy use and higher levels of depressive symptoms is currently unconvincing, but the frequent concomitant use of Ecstasy and other illicit drugs has been shown to be associated with higher levels of depressive symptoms. Possible causes include polydrug use in general, MDMA-induced serotonergic deficits, individual effects of illicit drugs besides Ecstasy, combined effects of MDMA and other illicit drugs, and preexisting differences in the levels of depressive symptoms in Ecstasy users.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17523583     DOI: 10.1080/02791072.2007.10399862

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  5 in total

1.  Ecstasy use and suicidal behavior among adolescents: findings from a national survey.

Authors:  Jueun Kim; Bin Fan; Xinhua Liu; Nancy Kerner; Ping Wu
Journal:  Suicide Life Threat Behav       Date:  2011-06-01

2.  Ecstasy use and depression: a 4-year longitudinal study among an Australian general community sample.

Authors:  Amanda M George; Sarah Olesen; Robert J Tait
Journal:  Psychopharmacology (Berl)       Date:  2013-05-17       Impact factor: 4.530

3.  Long-term neuropsychological effects of ecstasy in middle-aged ecstasy/polydrug users.

Authors:  Thelma Schilt; Maarten W J Koeter; Johan P Smal; Mathilde N Gouwetor; Wim van den Brink; Ben Schmand
Journal:  Psychopharmacology (Berl)       Date:  2009-10-13       Impact factor: 4.530

4.  MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology.

Authors:  P Sáez-Briones; A Hernández
Journal:  Curr Neuropharmacol       Date:  2013-09       Impact factor: 7.363

Review 5.  3,4-methylenedioxymethamphetamine (MDMA): current perspectives.

Authors:  Jerrold S Meyer
Journal:  Subst Abuse Rehabil       Date:  2013-11-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.